Vertex's (VRTX) last transformative acquisition took 11 years to pay off, what about the new Crinetics?

**TL;DR**

* **\~98%** of Vertex's product revenue still comes from cystic fibrosis drugs.
* That franchise came from a **2001** acquisition. The first drug out of it wasn't approved until **2012**, and it didn't become a giant until **\~2019**.
* The newer bets (Diabetes, Duchenne Muscular Dystrophy, Kidney disease) are all still pre-revenue. It just paid **\~$10B** cash for **Crinetics**.
* The tension: Patient franchise-builder, or serial buyer of pipelines that don't pay off?

\------------------

**\~98%** Vertex's revenue still comes from one disease, cystic fibrosis (**CF**). Their last transformative acquisition (**Aurora Biosciences**) took around **11** years to pay off, then basically became **98%** of the company, and last week they bought Crinetics in a **$10B** cash deal, the biggest acquisition in Vertex's history. Instead of popping on the news, the stock fell about **8%** this week (-7.95%), closing Friday (July 10) at **$485.39**, down from **\~$530** the day the deal was announced.

Of the **$3.0B** in product sales last quarter, **CF** was **$2.9B**. Vertex's own 10-K doesn't dress it up:

>"Substantially all our net product revenues have been derived from the sale of our CF medicines."

The two launches everyone points to, the CRISPR therapy **Casgevy** and the painkiller **Journavx**, were about **$72M** combined, roughly **2%** of revenue, even though Journavx has already crossed a **million** prescriptions.

This whole **CF** monopoly traces back to Vertex buying **Aurora Biosciences** in **2001** for **\~$592M**. The labs it acquired discovered **ivacaftor** in the **mid-2000s**, but the first CF drug, **Kalydeco**, wasn't approved until **2012**, eleven years after the deal, and it was tiny, about **$172M** that year. The franchise only became the **\~$12B** engine it is now once the combination drugs arrived: **Orkambi** (2015), then **Trikafta** (2019). Roughly eighteen years from acquisition to full payoff. (The billion-dollar revenue Vertex booked around **2011-2012** was mostly a **hepatitis C drug** that later collapsed, not CF.)

Look at the rest of the shopping list through the same lens. **Exonics** (*Duchenne Muscular Dystrophy,* **\~$245M, 2019**), **Semma** (*type 1 diabetes*, **\~$950M, 2019**), **ViaCyte** (*diabetes*, **\~$315M, 2022**), **Alpine** (*kidney and immune*, **\~$5B, 2024**): all still pre-revenue or barely launched, and only a few years in. If Aurora took eleven to eighteen years, it's early to call these dead. The bear says Vertex keeps buying pipelines that don't produce. The bull says give it a decade, like last time.

**Crinetics** (an **approved** acromegaly drug plus a **phase 3 asset, $10B**, **2026**) is the biggest investment yet. Even after this week's drop it trades around \~**29x** earnings, so the market still isn't pricing it cheaply, just less richly than before.

The question I think isn't just whether Vertex is too concentrated. It's whether the patience that built the CF monopoly is a repeatable blueprint, or whether 2001 was a one-off that's difficult to replicate. For anyone in pharma: how long do you give a Semma or an Alpine before pre-revenue just means it failed?

**My opinion**: This deal actually feels different from the others. Every earlier bet (Exonics, Semma, ViaCyte, even Alpine) was pre-approval pipeline, buy the science and wait years for trial readouts. Crinetics comes with **Palsonify**, an already **FDA-approved** **acromegaly drug** that launched in late **2025** and did **\~$10M** in **Q1 2026** and is growing. Vertex is buying a commercial product and its market infrastructure, not another decade-long "maybe." That shortens the payoff clock a lot, and I think they can afford to keep swinging because the CF cash cow is locked up: per Vertex's own filings, **Trikafta** (the bulk of revenue) is US-protected until **\~2037**, with the newer **Alyftrek** extending the franchise to **\~2039**, even as the older combos roll off sooner (Symdeko **\~2027**, Orkambi **\~2030-31**). So the revenue funding these bets is fairly stable into the mid-2030s, which buys time for one of them to become the next **Trikafta**.

You can find the full analysis on [The Current State of Vertex](https://open.substack.com/pub/secaura/p/the-current-state-of-vertex-vrtx?r=1jjx11&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true) on my **free** substack!